Merck (BSE:MRK) Gross-Profit-to-Asset % : 40.18% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Merck Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Merck's annualized Gross Profit for the quarter that ended in Dec. 2023 was lei199,089 Mil. Merck's average Total Assets over the quarter that ended in Dec. 2023 was lei495,499 Mil. Therefore, Merck's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 40.18%.

Merck Gross-Profit-to-Asset % Historical Data

The historical data trend for Merck's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Gross-Profit-to-Asset % Chart

Merck Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

32.45

31.71

35.56

38.98

40.76

Merck Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															36.81	38.94	41.50	44.31	40.18

Competitive Comparison of Merck's Gross-Profit-to-Asset %

For the Drug Manufacturers - General subindustry, Merck's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merck's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Merck's Gross-Profit-to-Asset % falls into.

Merck Gross-Profit-to-Asset % Calculation

Merck's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	204276.294	/	( (506917.645	+	495377.792)	/ 2 )
	=	204276.294	/	501147.7185
	=	40.76 %

Merck's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	199089.164	/	( (495619.27	+	495377.792)	/ 2 )
	=	199089.164	/	495498.531
	=	40.18 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Merck Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Merck's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck (BSE:MRK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (BSE:MRK) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

MRK:USA MRK:Peru MRK:Mexico 1MRKX:Italy 6MKd:UK 0QAH:UK 6MK:Germany 6MK:Germany 6MK:Germany 6MK:Germany MRK:Chile MRCK34:Brazil MRK:Austria MRK:Argentina

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.